Spyre Therapeutics Quarterly Balance Sheet
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Spyre Therapeutics financial position
As of Jun 30, 2026, Spyre Therapeutics reported total assets of $1.17 billion, up 117.7% from a year earlier against total liabilities of $71.9 million. Shareholders' equity stood at $1.10 billion, or 93.9% of assets. The company held $162.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 18.53, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Spyre Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 162.01M | 97.19M | 85.72M | 64.90M | 81.66M | 48.49M | 89.42M | 71.58M | 45.14M | 227.55M | 188.89M | 90.59M |
| Short-Term Investments | 983.34M | 644.28M | 670.81M | 421.30M | 444.92M | 516.33M | 513.66M | 342.65M | 380.85M | 257.09M | 150.38M | 113.01M |
| Total Current Assets | 1.17B | 763.95M | 777.78M | 504.60M | 538.83M | 569.77M | 608.47M | 421.08M | 435.74M | 487.27M | 341.53M | 205.95M |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Total Assets | 1.17B | 763.95M | 777.78M | 504.60M | 538.83M | 569.78M | 608.48M | 421.09M | 436.07M | 487.60M | 341.86M | 207.26M |
| Accounts Payable | — | — | — | — | — | — | — | 5.17M | 3.23M | 3.11M | 896.00K | 1.68M |
| Total Current Liabilities | 63.30M | 85.16M | 58.69M | 46.27M | 83.06M | 70.68M | 54.06M | 57.54M | 22.12M | 42.82M | 31.98M | 44.87M |
| Total Liabilities | 71.86M | 93.14M | 62.55M | 49.50M | 83.06M | 87.17M | 90.68M | 93.70M | 61.68M | 81.93M | 73.29M | 65.56M |
| Shareholders' Equity | 1.10B | 670.81M | 715.24M | 455.10M | 455.77M | 482.61M | 517.80M | 327.39M | 374.38M | 152.27M | 184.02M | -245.40M |
| Retained Earnings | -1.23B | -1.20B | -1.13B | -1.07B | -1.05B | -1.02B | -972.43M | -916.14M | -847.11M | -808.27M | -764.41M | -701.23M |
| Net Cash (Debt) | 1.15B | 741.47M | 756.53M | 486.20M | 526.58M | 564.82M | 603.09M | 414.23M | 426.00M | 484.64M | 339.28M | 203.60M |
| Shares Outstanding | 88.06M | 78.84M | 78.19M | 60.47M | 60.37M | 60.28M | 60.26M | 51.40M | 50.78M | 36.63M | 36.06M | 4.05M |
This table shows 12 quarterly periods of Spyre Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SYRE's reporting calendar. What is a balance sheet?